Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

* Data support ongoing Phase 2 “RENEW” trial * First-in-human clinical study produced measurable reductions in multiple markers of lung scarring and inflammation in IPF patients * Study confirms LTI-03 was safe and well-tolerated AUSTIN, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced publication of clinical data from its first-in-human study of LTI-03 in Nature Communications, one of the world's most prestigious peer-reviewed scientific journals. The paper, titled "Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study," is available at [https://www.nature.com/articles/s41467-026-75291-3]. These data were previously reported as a preprint in November 2025. Publication in Nature Communications following independent peer review represents significant scientific validation of the study design, data, and conclusions.